7TZC image
Entry Detail
PDB ID:
7TZC
EMDB ID:
Title:
A drug and ATP binding site in type 1 ryanodine receptor
Biological Source:
PDB Version:
Deposition Date:
2022-02-15
Release Date:
2022-05-18
Method Details:
Experimental Method:
Resolution:
2.45 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Ryanodine receptor 1
Chain IDs:F (auth: A), G (auth: B), H (auth: G), I
Chain Length:5037
Number of Molecules:4
Biological Source:Oryctolagus cuniculus
Polymer Type:polypeptide(L)
Description:Peptidyl-prolyl cis-trans isomerase FKBP1A
Chain IDs:B (auth: F), J (auth: H), K (auth: J), L (auth: O)
Chain Length:107
Number of Molecules:4
Biological Source:Oryctolagus cuniculus
Polymer Type:polypeptide(L)
Description:Calmodulin-1
Chain IDs:A (auth: K), C (auth: D), D (auth: E), E (auth: C)
Chain Length:150
Number of Molecules:4
Biological Source:Homo sapiens
Primary Citation
A drug and ATP binding site in type 1 ryanodine receptor.
Structure 30 1025 ? (2022)
PMID: 35580609 DOI: 10.1016/j.str.2022.04.010

Abstact

The ryanodine receptor (RyR)/calcium release channel on the sarcoplasmic reticulum (SR) is required for excitation-contraction coupling in skeletal and cardiac muscle. Inherited mutations and stress-induced post-translational modifications result in an SR Ca2+ leak that causes skeletal myopathies, heart failure, and exercise-induced sudden death. A class of therapeutics known as Rycals prevent the RyR-mediated leak, are effective in preventing disease progression and restoring function in animal models, and are in clinical trials for patients with muscle and heart disorders. Using cryogenic-electron microscopy, we present a model of RyR1 with a 2.45-Å resolution before local refinement, revealing a binding site in the RY1&2 domain (3.10 Å local resolution), where the Rycal ARM210 binds cooperatively with ATP and stabilizes the closed state of RyR1.

Legend

Protein

Chemical

Disease

Primary Citation of related structures